Curie Capital is a Life Sciences focused venture capital firm specialized in investing in early-stage companies, supporting talented teams with exciting new medical products.

Curie Capital

Curie Capital BV

Looking to connect with us? Coming week our associate Thom Frielink will be present at the Global Investor Forum (March 27) and Innovation for Health (March 28).

❕Today, Citryll is happy to announce the appointment of Maarten Kraan as our new Chief Medical Officer. 

We are very excited to have Maarten on board! As we begin a new chapter at Citryll, his experience will be invaluable in advancing CIT-013, our lead antibody, into Phase 2a proof-of-concept studies in rheumatoid arthritis and hidradenitis suppurativa.

➡ Take a look at our press release for the full details of this announcement: https://lnkd.in/dNjVwfsq

Curie Capital BV is proud to announce its latest investment: we are honored to continue our commitment to the newly named Flindr (formerly Immagene), as part of their €20 million Series A financing to advance first-in-class small molecule inhibitors. This round is led by V-Bio Ventures with an international syndicate which includes Johnson & Johnson Innovation JJDC Inc, Qbic Fund | Venture Capital, PMV, as well as seed investors Oncode Oncology Bridge Fund, Swanbridge Capital and Brabantse Ontwikkelings Maatschappij (BOM). Flindr (formerly Immagene) discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations. Their lead asset is a first-in-class small molecule inhibitor of the cancer driver RNF31. 

For more information, please see https://lnkd.in/eQ64JYH8

Curie Capital has exciting news from its clinical stage portfolio company #Citryll, developing CIT-013 to treat immune-mediated inflammatory diseases (IMIDs):

We welcome Eduardo Bravo (CEO) and Tim Schenk (CBO), who are joining the great team of Citryll!

https://lnkd.in/exsD57X8

CURI

NL:CURIECAPITAL

Curie Capital